Proactive Investors - Run By Investors For Investors

Integumen delivers higher-than-expected revenues, cuts losses

The Stoer For Men skin care range was at monthly break-even by year-end 2018.
Woman testing cosmetics
Integumen has recently moved into the clinical trials sector

Integumen PLC (LON:SKIN), the company behind the Labskin technology, said revenues in 2018 were ahead of previous expectations.

The company, which has developed a laboratory-grown skin that is used by cosmetics and pharmaceutical companies to see how their latest products will react to human skin, said revenue increased to £502,000 in 2018 from £238,000 in 2017.

READ Slimmed-down Integumen looking to AI for next stage of Labskin’s evolution

Revenue from continuing operations practically tripled to £274,000 from £93,000 the year before.

The loss before interest, tax, depreciation and amortisation narrowed to £1.25mln from £1.4mln the previous year following a cost-cutting initiative by the new management team.

“Integumen continues its strong momentum well into 2019. With a more focused business, and in line with our strategy, we have now been able to demonstrate our ability to grow, both organically and through the successful post year-end transactions. Our digital and physical team members, across all subsidiaries, continue to deliver consistent reliable revenue growth as we scale-up our new digital platform," said Gerard Brandon, the chief executive officer (CEO) of Integumen.

The company revealed that chairman Tony Richardson has resigned with immediate effect, to be replaced by Ross Andrews.

“Tony, as CEO of Venn Life Sciences, had the foresight to identify the potential of Labskin as early as 2014, when it was acquired by Venn and has nurtured it from an early stage technology company, through a spin-out and IPO in 2017,” Brandon said.

Richardson’s resignation removes any possible competitive conflict of interest with Venn Life.

Shares in Integumen were up 1.6% in early deals.

View full SKIN profile View Profile

Integumen Timeline

Big Picture
May 21 2019

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use